Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KLK8

KLK8

Basics

Aliases:
This biomarker is also known as:
  • PRSS19,
  • Serine protease 19,
  • Neuropsin,
  • NP,
  • ovasin,
  • Serine protease TADG-14,
  • kallikrein-related peptidase 8,
  • Ovasin,
  • NRPN,
  • HNP,
  • hK8,
  • kallikrein 8 (neuropsin/ovasin),
  • Tumor-associated differentially expressed gene 14 protein,
  • TADG14,
  • neuropsin,

View in BioMuta

Description…

KLK8, a member of the kallikrein subgroup of serine proteases, is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV. Kallikreins have been implicated in carcinogenesis, and some have potential as novel cancer and other disease biomarkers. KLK8 is one of fifteen kallikrein subfamily members located in a cluster on chromosome 19. The four isoforms of KLK8 are a result of alternate splicing of the gene. The isoforms exhibit distinct patterns of expression that suggest roles in brain plasticity and ovarian cancer.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

KLK8 alone was not shown to be a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html